Trial · NCT02322775
Results by group91
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 91
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (L) at Week 12 | Benralizumab 30 mg Q4W | Baseline | 2.248 | Standard Deviation 0.6062 | Litre |
| Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (L) at Week 12 | Placebo | Baseline | 2.246 | Standard Deviation 0.7677 | Litre |
| Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (L) at Week 12 | Benralizumab 30 mg Q4W | Week 12 | 2.310 | Standard Deviation 0.6702 | Litre |
| Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (L) at Week 12 | Placebo | Week 12 | 2.261 | Standard Deviation 0.7959 | Litre |
| Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (L) at Week 12 | Benralizumab 30 mg Q4W | Change from baseline at Week 12 | 0.057 | Standard Deviation 0.2734 | Litre |
| Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (L) at Week 12 | Placebo | Change from baseline at Week 12 | -0.016 | Standard Deviation 0.2350 | Litre |
| Change From Baseline in Morning Peak Expiratory Flow (PEF) (L/Min) at Home at Week 12 | Benralizumab 30 mg Q4W | Baseline | 307.413 | Standard Deviation 95.9467 | L/min |
| Change From Baseline in Morning Peak Expiratory Flow (PEF) (L/Min) at Home at Week 12 | Placebo | Baseline | 308.226 | Standard Deviation 113.5895 | L/min |
| Change From Baseline in Morning Peak Expiratory Flow (PEF) (L/Min) at Home at Week 12 | Benralizumab 30 mg Q4W | Week 12 | 311.041 | Standard Deviation 101.8169 | L/min |
| Change From Baseline in Morning Peak Expiratory Flow (PEF) (L/Min) at Home at Week 12 | Placebo | Week 12 | 304.037 | Standard Deviation 113.2538 | L/min |
| Change From Baseline in Morning Peak Expiratory Flow (PEF) (L/Min) at Home at Week 12 | Benralizumab 30 mg Q4W | Change from baseline at Week 12 | 1.675 | Standard Deviation 56.5182 | L/min |
| Change From Baseline in Morning Peak Expiratory Flow (PEF) (L/Min) at Home at Week 12 | Placebo | Change from baseline at Week 12 | -6.196 | Standard Deviation 45.3077 | L/min |
| Change From Baseline in Evening Peak Expiratory Flow (PEF) (L/Min) at Home at Week 12 | Benralizumab 30 mg Q4W | Baseline | 326.948 | Standard Deviation 97.4034 | L/min |
| Change From Baseline in Evening Peak Expiratory Flow (PEF) (L/Min) at Home at Week 12 | Placebo | Baseline | 316.743 | Standard Deviation 116.6919 | L/min |
| Change From Baseline in Evening Peak Expiratory Flow (PEF) (L/Min) at Home at Week 12 | Benralizumab 30 mg Q4W | Week 12 | 330.719 | Standard Deviation 106.7579 | L/min |
| Change From Baseline in Evening Peak Expiratory Flow (PEF) (L/Min) at Home at Week 12 | Placebo | Week 12 | 316.047 | Standard Deviation 118.7000 | L/min |
| Change From Baseline in Evening Peak Expiratory Flow (PEF) (L/Min) at Home at Week 12 | Benralizumab 30 mg Q4W | Change from baseline at Week 12 | 1.361 | Standard Deviation 51.9979 | L/min |
| Change From Baseline in Evening Peak Expiratory Flow (PEF) (L/Min) at Home at Week 12 | Placebo | Change from baseline at Week 12 | -2.956 | Standard Deviation 47.9136 | L/min |
| Change From Baseline in Total Asthma Symptom Score at Week 12 | Benralizumab 30 mg Q4W | Baseline | 1.934 | Standard Deviation 0.9310 | Scores on a scale |
| Change From Baseline in Total Asthma Symptom Score at Week 12 | Placebo | Baseline | 1.952 | Standard Deviation 1.0375 | Scores on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02322775/results